Moreover, as PIK3CA mutations are more common in ER+ BC [56], hormone receptor status, particularly estrogen receptor (ER) positivity, is associated with the potential efficacy of PI3K inhibitors in this subtype. This evidence concerns the gene PIK3CB and breast cancer.